96,354 results on '"Ovarian Neoplasms"'
Search Results
102. Combined Program of Supervised Physical Exercise and Nutritional Counseling in Ovarian Cancer Patients on Frontline Maintenance Treatment With PARP Inhibitors
103. Testing Olaparib for One or Two Years, With or Without Bevacizumab, to Treat Ovarian Cancer
104. NYSCF Scientific Discovery Biobank
105. Rectosigmoid Resection vs Seromuscular Tumor Shaving in Ovarian Cancer Surgery
106. TORC1/2 Inhibitor MLN0128 and Bevacizumab in Treating Patients With Recurrent Glioblastoma or Advanced Solid Tumors
107. Feasibility Study: IGNITE-TX (Identifying Individuals for Genetic Testing & Treatment) Intervention
108. A Phase II Study Of Nivolumab/ Bevacizumab/Rucaparib
109. Neoadjuvant RC48 Plus Carboplatin for HER2-expressing Advanced Ovarian Cancer
110. REFRaME-O1: A Study to Investigate the Efficacy and Safety of Luveltamab Tazevibulin Versus Investigator's Choice (IC) Chemotherapy in Women With Ovarian Cancer (Including Fallopian Tube or Primary Peritoneal Cancers) Expressing FOLR1
111. HS-20089 in Patients With Ovarian Cancer and Endometrial Cancer
112. Alpelisib Plus Olaparib in Platinum-resistant/Refractory, High-grade Serous Ovarian Cancer, With no Germline BRCA Mutation Detected
113. Pembrolizumab, Carboplatin, and Paclitaxel in Treating Patients With Stage III-IV Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
114. 68Ga-FAPI PET/CT in the Staging of High-Grade Epithelial Ovarian Cancers: A Pilot Study (FAST HOC)
115. Predicting Outcome of Cytoreduction in Advanced Ovarian Cancer, Using a Machine Learning Algorithm and Patterns of Disease Distribution at Laparoscopy (PREDAtOOR) (PREDAtOOR)
116. Niraparib and Selenium for the Treatment of Recurrent BRCA Negative Platinum Resistant Ovarian Cancer
117. Infertility Survey Among Reproductive Age Women With Gynecological and Breast Cancer
118. Intraperitoneal Cytokine-Induced Memory Like (CIML) Natural Killer (NK) Cells in Recurrent Ovarian Cancer
119. RC88 in Platinum-Resistant Recurrent Epithelial Ovarian Cancer, Fallopian Tube Cancer, and Primary Peritoneal Cancer
120. ETC-159 In Combination With Pembrolizumab In Advanced MSS/pMMR Ovarian Cancers (ETC-159-02)
121. Clonal Hematopoiesis in Ovarian Cancer Survivors and Risk of Secondary Blood Cancers, CHANCES Study
122. Safety and Efficacy of Anti-CD47, ALX148 in Combination With Liposomal Doxorubicin and Pembrolizumab in Recurrent Platinum-resistant Ovarian Cancer
123. A Study of Ocular Toxicity Evaluation and Mitigation During Treatment With Mirvetuximab Soravtansine in Participants With Recurrent Ovarian Cancer With High Folate Receptor-Alpha Expression
124. Talazoparib and Radiation Therapy in Treating Patients With Locally Recurrent Gynecologic Cancers
125. Study on the Relative Dose Intensity of PARP Inhibitors in Real-life on a Population of Patients Over 70 Years With Advanced Ovarian Cancer (PARIB-OLD-PRO²)
126. Pilot Study of Liposomal Bupivacaine Redosing in Patients Undergoing Major Gynecologic Procedures
127. Heated Intra-peritoneal Chemotherapy With Doxorubicin and Cisplatin for Abdominal for Pelvic Tumors in Pediatric Patients (TOASTIT)
128. A Study of CBX 12 in Subjects With Platinum Resistant or Refractory Ovarian Cancer
129. Autologous Tumor Infiltrating Lymphocytes MDA-TIL in Treating Patients With Recurrent or Refractory Ovarian Cancer, Colorectal Cancer, or Pancreatic Ductal Adenocarcinoma
130. A Study to Evaluate the Efficacy and Safety of JPI-547 in Platinum-resistant, Advanced/Relapsed Ovarian Cancer Subjects Previously Treated With a PARP Inhibitor
131. Surufatinib Combined With Carboplatin/Paclitaxel and Surufatinib Combined With Olaparib as First-line and Maintenance Therapy for Newly Diagnosed High-risk Ovarian Cancer
132. Olaparib Maintenance Monotherapy in Patients With BRCA Mutated Ovarian Cancer Following First Line Platinum Based Chemotherapy. (SOLO-1)
133. Study of ASP0739 Alone and With Pembrolizumab in Advanced Solid Tumors With NY-ESO-1 Expression Participants
134. Pamiparib Combined With Surufatinib for the Neoadjuvant Treatment of Unresectable Ovarian Cancer
135. Cancer Stem Cell Assay Directed Chemotherapy in Recurrent Platinum Resistant Ovarian Cancer
136. A Study Combining the Peposertib (M3814) Pill With Standard Chemotherapy in Patients With Ovarian Cancer With an Expansion in High Grade Serous Ovarian Cancer and Low Grade Serous Ovarian Cancer
137. D9319C00001- 1L OC Mono Global RCT (MONO-OLA1)
138. Avastin Plus Chemotherapy vs. Avastin Plus Chemotherapy Guided by Cancer Stem Cell Test in Recurrent Ovarian Cancer (ACSCO)
139. Phase 1, Safety and Tolerability Study of XmAb®541 in Advanced Solid Tumors
140. Promitil Treatment of Patients With Solid Tumors Associated With Deleterious Mutations Who Have Progressed After Therapy
141. SynKIR-110 for Mesothelin Expressing Ovarian Cancer, Cholangiocarcinoma or Mesothelioma
142. Study Evaluating Safety, Tolerability, and Metabolism of Niraparib
143. Clinical Study on the Re-irradiation of Lateral Pelvic Recurrences of Gynecological Malignancies (CYCLOPS)
144. A Cohort Study of Genetic Ovarian Cancer Risk Prediction Models and Pathogenesis Exploration
145. Pembrolizumab With Chemotherapy and MK-4830 for Treating Participants With Ovarian Cancer (MK-4830-002)
146. Adapting Multiple Behavior Interventions That Effectively Improve Cancer Survivor Health Cancer Survivor Health (AMPLIFY)
147. Recurrent Ovarian CarcinoSarcoma Anti-pd-1 Niraparib (ROCSAN)
148. Vaccine Therapy and Cyclophosphamide in Treating Patients With Stage II-III Breast or Stage II-IV Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
149. Cost of Cancer Risk Management in Women at Elevated Genetic Risk for Ovarian Cancer Who Participated on GOG-0199
150. A Phase I/II Trial of UCB4594 in Participants With Advanced Cancer
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.